Q2 EPS Estimates for Immix Biopharma Increased by Analyst

Immix Biopharma, Inc. (NASDAQ:IMMX) – Research analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for shares of Immix Biopharma in a research report issued to clients and investors on Friday, May 22nd. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.15) per share for the quarter, up from their previous forecast of ($0.18). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.62) EPS.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01.

A number of other equities analysts have also recently issued reports on IMMX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Tuesday, April 21st. Morgan Stanley started coverage on Immix Biopharma in a research note on Wednesday, March 25th. They set an “overweight” rating and a $20.00 price objective for the company. Mizuho increased their target price on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Monday, March 30th. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $23.00 price target on shares of Immix Biopharma in a research report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Immix Biopharma presently has an average rating of “Moderate Buy” and an average target price of $19.50.

Immix Biopharma Stock Up 0.7%

IMMX stock opened at $8.84 on Wednesday. Immix Biopharma has a twelve month low of $1.87 and a twelve month high of $11.61. The company has a market cap of $480.98 million, a P/E ratio of -9.61 and a beta of 0.12. The business has a fifty day moving average of $9.41 and a 200-day moving average of $7.20.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IMMX. Allworth Financial LP purchased a new position in Immix Biopharma in the fourth quarter worth about $30,000. Mathes Company Inc. purchased a new position in shares of Immix Biopharma in the fourth quarter worth approximately $56,000. Balyasny Asset Management L.P. bought a new stake in Immix Biopharma during the fourth quarter valued at approximately $67,000. Kera Capital Partners Inc. bought a new position in Immix Biopharma in the fourth quarter worth approximately $68,000. Finally, Velan Capital Investment Management LP increased its stake in shares of Immix Biopharma by 40.0% in the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock worth $73,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.